Velactis
cabergoline
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for this product has not been renewed by the marketing authorisation holder and is now withdrawn.
This EPAR was last updated on 25/01/2021
Authorisation details
| Product details | |
|---|---|
| Name |
Velactis
|
| Agency product number |
EMEA/V/C/003739
|
| Active substance |
cabergoline
|
| International non-proprietary name (INN) or common name |
cabergoline
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QG02CB03
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Ceva Santé Animale
|
| Revision |
1
|
| Date of issue of marketing authorisation valid throughout the European Union |
09/12/2015
|
| Contact address | |
Product information
11/12/2020 Velactis - EMEA/V/C/003739 -
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
-
Genito urinary system and sex hormones
-
Other gynecologicals
-
Prolactine inhibitors
Therapeutic indication
Therapeutic indication
For use in the herd management programme of dairy cows as an aid in the abrupt drying-off by reducing milk production to:
- reduce milk leakage at drying off;
- reduce the risk of new intramammary infections during the dry period;
- reduce discomfort.